牙髓炎中神经肽表达的系统综述与Meta分析
结果显示SP、CGRP、神经激肽A和神经肽Y在牙髓炎牙中翻译后表达一致升高,合并效应量大(SMD 2.88,CI:2.00-3.77),但异质性大、研究质量中等,临床诊断价值尚不确定。
要点
- SP和CGRP在症状性不可复性牙髓炎中升高最一致,可作为候选生物标志物。
- 神经肽升高可能主要源于神经元分泌而非局部合成。
- 证据异质性大且缺乏诊断准确性研究,临床用于指导活髓治疗决策尚不明确。
核心结论
- 神经肽在症状性不可复性牙髓炎中一致升高,尤其是SP和CGRP,可能为牙髓炎症的候选生物标志物。
- 当前证据提示神经肽表达主要经神经元分泌而非局部合成。
- 因异质性大、研究质量中等且缺乏诊断准确性研究,其临床效用仍不确定。
研究设计与样本
- 系统综述与Meta分析,遵循PRISMA指南并在PROSPERO注册(CRD42024600828)。
- 检索MEDLINE、Embase、Web of Science和Scopus四个数据库的英文研究。
- 两名评价者独立筛选、提取数据并使用QUIN工具评估偏倚风险,分歧由第三名评价者解决。
- Meta分析采用随机效应和固定效应模型,并按神经肽类型和表达水平进行亚组分析。
主要发现
- 牙髓炎牙与对照相比,SP、CGRP、神经激肽A和神经肽Y的翻译后表达一致增加。
- 一项研究还显示CGRP转录后上调。
- 血管活性肠肽表达结果不一致,secretoneurin仅显示升高趋势。
- Meta分析显示合并效应量大(SMD 2.88,CI:2.00-3.77),亚组效应显著且异质性大。
- SP和CGRP在各研究中升高最强且最一致。
关键数值与推荐
- 合并效应量SMD为2.88(CI:2.00-3.77)。
- 偏倚风险以中等为主。
- 缺乏诊断准确性研究。
临床怎么用
- SP和CGRP可作为牙髓炎症的候选生物标志物,但尚不能常规用于临床诊断。
- 神经肽表达主要反映神经元分泌,提示神经源性炎症在症状性不可复性牙髓炎中的作用。
- 现有证据不足以指导活髓治疗决策。
局限性
- 研究间异质性大。
- 研究质量中等,偏倚风险以中等为主。
- 缺乏诊断准确性研究。
- 需要进一步高质量研究整合基因和蛋白分析与标准化临床诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neuropeptides play key roles in the inflammatory, nociceptive and reparative processes of the dental pulp. Their upregulation has been frequently observed in inflamed pulps, suggesting potential diagnostic value supporting a role for neurogenic inflammation in symptomatic irreversible pulpitis. OBJECTIVES: This systematic review and meta-analysis aimed to evaluate evidence for neuropeptide expression at post-transcriptional and post-translational levels in human teeth diagnosed with symptomatic irreversible pulpitis. METHOD: The review followed PRISMA guidelines and was registered on PROSPERO. Four databases (MEDLINE, Embase, Web of Science and Scopus) were searched for English-language studies investigating neuropeptide RNA or protein expression in human permanent teeth. Two reviewers independently performed study selection, data extraction and risk-of-bias assessment using the Quality Assessment Tool for In Vitro Studies (QUIN) tool, with conflicts resolved by a third reviewer. Meta-analysis was conducted using random- and fixed-effects models, with subgroup analyses by neuropeptide type and expression level. Studies lacking sufficient quantitative data were included in a narrative synthesis. RESULTS: Fourteen observational studies involving 588 teeth met the inclusion criteria. Limited evidence of neuropeptide synthesis for calcitonin gene-related peptide (CGRP) in the pulp was identified. However, consistent post-translational increased expression of Substance P (SP), CGRP, neurokinin A and neuropeptide Y was observed in pulpitic teeth compared with controls. One study additionally demonstrated post-transcriptional CGRP upregulation. Vasoactive intestinal peptide expression showed inconsistent findings, and secretoneurin showed a trend of increase only. Meta-analysis demonstrated a large, pooled effect size (SMD 2.88, CI: 2.00-3.77) with significant subgroup effects and substantial heterogeneity. SP and CGRP showed the strongest and most consistent increases across studies. Risk of bias was predominantly medium. CONCLUSION: Neuropeptides are consistently elevated in symptomatic irreversible pulpitis, particularly **SP** and **CGRP**, and may represent candidate biomarkers of pulpal inflammation. Current evidence suggests expression occurs predominantly via neuronal secretion rather than local synthesis. Despite consistent associations with pulpal inflammation, substantial heterogeneity, moderate study quality and the absence of diagnostic accuracy studies mean that their clinical utility remains uncertain. Further high-quality research integrating gene and protein analyses with standardised clinical diagnostics is needed to define their role in guiding vital pulp treatment decisions. TRAIL REGISTRATION: The study protocol was registered in the international prospective register of systematic reviews (PROSPERO) (CRD42024600828).
引用
- Watson N, Edwards D, Vuong Q, et al. The Expression of Neuropeptides in Pulpitis: A Systematic Review and Meta-Analysis. Int Endod J. 2026. PMID: 42713633. doi:10.1111/iej.70267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。